Breaking News

Phlow Receives $35M in Funding to Improve the U.S. Medicine Supply Chain

The capital raised will be leveraged to expand commercial offerings, including the rapid growth of its CDMO program, cdmoX.

Phlow Corp., a U.S.-based public benefit corporation and contract development and manufacturing organization (CDMO), closed a $36 million Series B capital raise as part of its mission to protect America’s medicine cabinet. Since its launch in 2020, Phlow has been working to leverage advanced development and manufacturing processes to reimagine the domestic production of key starting materials (KSM), active pharmaceutical ingredients (API), and finished pharmaceutical products that are critica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters